Overview

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

Status:
Terminated

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant.

Phase:

Phase 2

Details

Lead Sponsor:

Tarix Pharmaceuticals

Collaborator:

Constant Therapeutics LLC

Treatments:

Angiotensin I (1-7)